Telitacicept may reduce proteinuria in patients with high-risk IgA nephropathy

1. In this interim analysis from a randomized controlled trial, adults with biopsy-proven IgA nephropathy and persistent proteinuria who received telitacicept had improved proteinuria compared to placebo. 2. Telitacicept was associated with more overall adverse events but fewer serious adverse events and more stable kidney function. Evidence Rating Level: 1 (Excellent) Study Rundown: IgA…